A V Diudin

City Hospital No. 26, Saint Petersburg, Russia.

2 publications 1986 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does A V Diudin research?

A V Diudin studies the treatment of ischemic stroke, a type of stroke that occurs when a blood clot blocks blood flow to the brain. They specifically investigate how well the medication Revelise, which helps dissolve blood clots, performs in actual clinical settings rather than controlled trials. The research involves analyzing large groups of patients to understand the effectiveness and safety of this treatment, especially among older individuals and those with additional health challenges.

Key findings

  • In a study involving 2,202 patients, nearly half (49.9%) experienced good outcomes when discharged from the hospital after thrombolytic therapy with Revelise.
  • The percentage of patients with good outcomes increased to 66.4% after 90 days, indicating long-term benefits of the treatment.
  • Revelise was found to effectively reduce stroke-related disabilities, demonstrating its usefulness for older patients and those with other medical conditions.

Frequently asked questions

Does Dr. Diudin study ischemic strokes?
Yes, Dr. Diudin focuses on the treatment and outcomes of ischemic strokes.
What treatments has Dr. Diudin researched?
Dr. Diudin has researched the medication Revelise (alteplase) for treating ischemic stroke.
Is Dr. Diudin's work relevant to older stroke patients?
Yes, their research specifically addresses the effectiveness of treatments in older patients and those with additional health challenges.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

[Methodological bases for the telethermodiagnosis of diseases and injuries of the locomotor apparatus].

1986

Ortopediia travmatologiia i protezirovanie

Ternovoĭ NK, Rozenfel'd LG, Samokhin AV, Derzhavin AE, Diudin AV

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.